Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)WARSAW, Poland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Molecure S.A. (WSE: MOC), a clinical-stage biotechnology company, has received a positive recommendation from the IDMC to continue the Phase II KITE clinical trial without protocol changes. The trial evaluates the efficacy and safety of OATD-01, a first-in-class CHIT1 inhibitor, in active pulmonary sarcoidosis patients.
